Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pilot safety and tolerability study of ILB in ALS/MND
2018-000668-28Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ilb in amyotrophic lateral sclerosis (ALS) and motor neuron disease (MND), sponsored by University of Birmingham. Primary endpoint: Feasibility, safety and tolerability of ILB. Status: unknown.
02
Drugs
ilb
03
Conditions
amyotrophic lateral sclerosis (ALS)motor neuron disease (MND)
Beyond the preview
Go deeper on 2018-000668-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000668-28.